NASDAQ · EQRX
Healthcare · Biotechnology
$2.34
Down-$0.05 (-2.09%)
Updated Oct 6, 2026, 11:22 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EQRX
1M range · 0 trading sessions · Daily adjusted prices
EQRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning EQRX.
Company
Market Activity
Research & News
EQRX research
Company profile and research snapshot.
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 10, 2023 | Goldman Sachs | Neutral | — |
| Nov 14, 2022 | JP Morgan | Underweight | — |
| Nov 11, 2022 | Goldman Sachs | Neutral | — |
| Nov 11, 2022 | Jefferies | Hold | — |
| Aug 16, 2022 | JP Morgan | Neutral | — |
No generated briefing is available yet.
PennyStocks · Oct 17, 2023
3 Hot Penny Stocks To Watch This Week The post Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research · Aug 9, 2023
EQRx (EQRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PennyStocks · Aug 2, 2023
Best penny stocks to watch this week? 3 for your penny stocks watch list The post Best Penny Stocks To Watch After Fitch Downgrade? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga · Aug 1, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC) jumped 49% to $15.03 amid claims of a new superconductor from a group of physicists. Nikola Corporation (NASDAQ: NKLA) gained 21% to $3.22. The company announced it was awarded an additional $16.3 million to support seven open-network hydrogen refueling stations. Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) rose 19% to $21.24 following strong quarterly sales. Arista Networks, Inc. (NYSE: ANET) surged 18.7% to $184.21 after the company reported better-than-expected quarterly results. AudioCodes Ltd. (NASDAQ: AUDC) shares rose 16.2% to $11.66 following upbeat second-quarter earnings. EQRx, Inc. (NASDAQ: EQRX) shares gained 14.3% to $1.9550. Revolution Medicines announced plans ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EQRX.
No results
No recent SID articles mention EQRX.
